ELEPHAS PUBLISHES PEER-REVIEWED DATA IN CELL REPORTS MEDICINE DEMONSTRATING elive™ PLATFORM'S IMMUNOTHERAPY RESPONSE MEASUREMENT

Study Demonstrates 93% Accuracy in Predicting Clinical Benefit and Highlights the Platform's Potential to Enhance Clinical Decision Making MADISON, Wis., Oct. 15, 2026 /PRNewswire/ -- Elephas Biosciences Corporation, a private company that has developed an innovative live tissue platform...

Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.